Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 4 May 2018 - As part of the up to DKK 14 billion 2018 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 2.7 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour Rules.
For that purpose, Novo Nordisk A/S has appointed Nordea Danmark, filial af Nordea Bank AB (publ) as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company's share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, Nordea Danmark, filial af Nordea Bank AB (publ) will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 7 May and ending on 6 August 2018. A maximum of 531,624 B shares can be bought during one single trading day, equal to 20% of the average daily trading volume of Novo Nordisk B shares on Nasdaq Copenhagen during the month of April 2018, and a maximum of 32,960,688 B shares in total can be bought during the trading period. At least once every seven trading days, Novo Nordisk A/S will issue an announcement in respect of the transactions made under the repurchase programme.
Further information
Media: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
Christina Kjær | +45 3079 3009 | cnje@novonordisk.com |
Company announcement No 40/2018
PR180504_SH_initiation_UK
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
\Hugin